Relmada Therapeutics (RLMD) Change in Cash (2012 - 2026)
Relmada Therapeutics (RLMD) reported Change in Cash of $6.3 million for Q1 2026, up 331.96% year-over-year from $1.5 million in Q1 2025, and up 197.33% on a QoQ basis from $2.1 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Change in Cash data on file, last reported at $6.3 million in Q1 2026.
- Quarterly Change in Cash rose 331.96% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 4755.23% YoY) and the FY2025 annual result came in at -$360486.0, down 53.7% from the prior year.
- Change in Cash climbed to $6.3 million in Q1 2026 per RLMD's latest filing, from $2.1 million in the prior quarter.
- Across five years, Change in Cash topped out at $23.5 million in Q1 2023 and bottomed at -$37.1 million in Q4 2022.
- The 5-year median for Change in Cash is $31133.0 (2025), against an average of -$2.0 million.
- The widest annual swing landed in 2022, when Change in Cash plunged 986.8%; it then surged 4686.45% in 2023.
- Tracing RLMD's Change in Cash over 5 years: stood at -$37.1 million in 2022, then surged by 92.98% to -$2.6 million in 2023, then surged by 191.03% to $2.4 million in 2024, then fell by 11.01% to $2.1 million in 2025, then jumped by 197.33% to $6.3 million in 2026.
- Per Business Quant, the three latest RLMD Change in Cash figures stand at $6.3 million (Q1 2026), $2.1 million (Q4 2025), and $31133.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 6.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.28 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 31,133.00 |
| Jun 30, 2025 | 203,645.00 |
| Mar 31, 2025 | -2.71 Mn |
| Dec 31, 2024 | 2.37 Mn |
| Sep 30, 2024 | -602,471.00 |
| Jun 30, 2024 | 751,242.00 |
| Mar 31, 2024 | -2.76 Mn |
| Dec 31, 2023 | -2.61 Mn |
| Sep 30, 2023 | -7.77 Mn |
| Jun 30, 2023 | -14.43 Mn |
| Mar 31, 2023 | 23.50 Mn |
| Dec 31, 2022 | -37.13 Mn |
| Sep 30, 2022 | 5.26 Mn |
| Jun 30, 2022 | -7.67 Mn |
| Mar 31, 2022 | 490,937.00 |
| Dec 31, 2021 | 32.99 Mn |
| Sep 30, 2021 | 6.78 Mn |
| Jun 30, 2021 | 865,303.00 |
| Mar 31, 2021 | 1.31 Mn |
| Dec 31, 2020 | -5.05 Mn |
| Sep 30, 2020 | -6.28 Mn |
| Jun 30, 2020 | 1.60 Mn |
| Mar 31, 2020 | -24.05 Mn |
| Dec 31, 2019 | 27.06 Mn |
| Sep 30, 2019 | -1.37 Mn |
| Jun 30, 2019 | 4.43 Mn |
| Mar 31, 2019 | -372,898.00 |
| Dec 31, 2018 | -5.24 Mn |
| Sep 30, 2018 | -1.35 Mn |
| Mar 31, 2018 | -1.68 Mn |
| Dec 31, 2017 | 1.25 Mn |
| Sep 30, 2017 | 2.97 Mn |
| Jun 30, 2017 | -1.05 Mn |
| Mar 31, 2017 | -1.96 Mn |
| Dec 31, 2016 | -1.51 Mn |
| Sep 30, 2016 | -2.28 Mn |
| Jun 30, 2016 | -2.85 Mn |
| Mar 31, 2016 | -3.78 Mn |
| Dec 31, 2015 | -4.04 Mn |
| Sep 30, 2015 | -3.30 Mn |
| Jun 30, 2015 | -4.49 Mn |
| Mar 31, 2015 | -4.46 Mn |
| Dec 31, 2014 | 4.03 Mn |
| Sep 30, 2014 | 1.83 Mn |
| Jun 30, 2014 | 22.04 Mn |
| Mar 31, 2014 | 899,404.00 |
| Nov 30, 2013 | -9,124.00 |
| Feb 28, 2013 | -2,942.00 |
| Nov 30, 2012 | 1,497.00 |
| Aug 31, 2012 | -3,344.00 |
| May 31, 2012 | 7,514.00 |